The Effect of Immunosuppression on Coagulation After Liver Transplantation
Sotiria Bedreli, Katja Straub, Anne Achterfeld, Katharina Willuweit, Antonios Katsounas, Fuat Saner, Heiner Wedemeyer, Kerstin Herzer – 25 April 2019 – Everolimus (EVR) is a mammalian target of rapamycin (mTOR) inhibitor commonly used for immunosuppression (IS) after liver transplantation (LT). However, there are concerns about whether mTOR inhibitors may move the hemostatic balance toward a higher likelihood of thrombosis. The present study aimed to investigate potential coagulation disorders after the administration of EVR.